Changing perspective on oncometabolites: From metabolic signature of cancer to tumorigenic and immunosuppressive agents

Oncotarget

Volumn 7, Issue 29, 2016, Pages 46692-46706

  Corrado, Mauro ^a,b   Scorrano, Luca ^a,c   Campello, Silvia ^b,d  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer; Immune response; Lymphocytes; Metabolism

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE 1; CD8 ANTIGEN; CHEMOKINE; FUMARATE HYDRATASE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; ISOCITRATE DEHYDROGENASE; LACTIC ACID; MYC PROTEIN; PROTEIN P53; RAS PROTEIN; SUCCINATE DEHYDROGENASE; VASCULOTROPIN;

AGGRESSIVENESS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELL POLARITY; GLYCOLYSIS; HUMAN; INFLAMMATORY CELL; METABOLIC REGULATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REVIEW; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GENE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CARCINOGENESIS; CELL PROLIFERATION; CITRIC ACID CYCLE; ENERGY METABOLISM; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

CARCINOGENESIS; CELL POLARITY; CELL PROLIFERATION; CITRIC ACID CYCLE; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MACROPHAGES; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84979944251     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8727     Document Type: Review

References (160)

1. Hanahan D, Weinberg R A. The hallmarks of cancer. Cell. 2000; 100, 57-70.
2. Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation. Cell. 2011; 144, 646-674.
3. Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411, 342-348.
4. Vander Heiden M G, Cantley L C, Thompson C B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324, 1029-1033.
5. Slater E C. Mechanism of oxidative phosphorylation. Annu Rev Biochem. 1977; 46, 1015-1026.
6. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927; 8, 519-530.
7. Warburg O. On respiratory impairment in cancer cells. Science. 1956; 124, 269-270.
8. McAllister R M. Search for oncogenes in human rhabdomyosarcoma cells. Prog Immunobiol Stand. 1971; 5, 237-242.
9. Newmark P. Tyrosine phosphorylation and oncogenes. Nature. 1981; 292, 15-16.
10. Meier H, Huebner RJ. Host-gene control of C-type tumor virus-expression and tumorigenesis: relevance of studies in inbred mice to cancer in man and other species. Proc Natl Acad Sci U S A. 1971; 68, 2664-2668.
11. McDonnell T J, Deane N, Platt F M, Nunez G, Jaeger U, McKearn J P, Korsmeyer S J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989; 57, 79-88.
12. Vaux D L, Cory S, Adams J M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335, 440-442.
13. Hockenbery D, Nunez G, Milliman C, Schreiber R D, Korsmeyer S J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990; 348, 334-336.
14. Liu X, Kim C N, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996; 86, 147-157.
15. Harvey A J, Kind K L, Thompson J G. REDOX regulation of early embryo development. Reproduction. 2002; 123, 479-486.
16. Rafalski V A, Mancini E, Brunet A. Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate. J Cell Sci. 2012; 125, 5597-5608.
17. Wang R, Green D R. Metabolic checkpoints in activated T cells. Nat Immunol. 2012; 13, 907-915.
18. Baysal B E, Ferrell R E, Willett-Brozick J E, Lawrence E C, Myssiorek D, Bosch A, van der Mey A, Taschner P E, Rubinstein W S, Myers E N, Richard C W r, Cornelisse C J, Devilee P et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287, 848-851.
19. Tomlinson I P, Alam N A, Rowan A J, Barclay E, Jaeger E E, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance R R, Olpin S, Bevan S et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002; 30, 406-410.
20. Colegio O R, Chu N Q, Szabo A L, Chu T, Rhebergen A M, Jairam V, Cyrus N, Brokowski C E, Eisenbarth S C, Phillips G M, Cline G W, Phillips A J, Medzhitov R. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014; 513, 559-563.
21. Frezza C. The role of mitochondria in the oncogenic signal transduction. Int J Biochem Cell Biol. 2014; 48, 11-17.
22. Miller D M, Thomas S D, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012; 18, 5546-5553.
23. Lombardi L, Newcomb E W, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBVinfected human B lymphoblasts. Cell. 1987; 49, 161-170.
24. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins J R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000; 14, 2501-2514.
25. Shim H, Dolde C, Lewis B C, Wu C S, Dang G, Jungmann R A, Dalla-Favera R, Dang C V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997; 94, 6658-6663.
26. Dang C V, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15, 6479-6483.
27. Kim J W, Gao P, Liu Y C, Semenza G L, Dang C V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007; 27, 7381-7393.
28. Osthus R C, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee L A, Dang C V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000; 275, 21797-21800.
29. Wise D R, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X Y, Pfeiffer H K, Nissim I, Daikhin E, Yudkoff M, McMahon S B, Thompson C B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008; 105, 18782-18787.
30. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11, 761-774.
31. Gough D J, Corlett A, Schlessinger K, Wegrzyn J, Larner A C, Levy D E. Mitochondrial STAT3 supports Rasdependent oncogenic transformation. Science. 2009; 324, 1713-1716.
32. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao P J, Keating M J, Garcia-Manero G et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 2012; 22, 399-412.
33. Lee M H, Lee S E, Kim D W, Ryu M J, Kim S J, Kim S J, Kim Y K, Park J H, Kweon G R, Kim J M, Lee J U, De Falco V, Jo Y S et al. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab. 2011; 96, E19-30.
34. Guo J Y, Chen H Y, Mathew R, Fan J, Strohecker A M, Karsli-Uzunbas G, Kamphorst J J, Chen G, Lemons J M, Karantza V, Coller H A, Dipaola R S, Gelinas C et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011; 25, 460-470.
35. Tsuneoka M, Umata T, Kimura H, Koda Y, Nakajima M, Kosai K, Takahashi T, Takahashi Y, Yamamoto A. c-myc induces autophagy in rat 3Y1 fibroblast cells. Cell Struct Funct. 2003; 28, 195-204.
36. Galluzzi L, Pietrocola F, Bravo-San Pedro J M, Amaravadi R K, Baehrecke E H, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015; 34, 856-880.
37. Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini P F, De Zio D, Nazio F, Antonioli M, D'Orazio M, Skobo T, Bordi M, Rohde M et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat Cell Biol. 2015; 17, 706.
38. Goldsmith J, Levine B, Debnath J. Autophagy and cancer metabolism. Methods Enzymol. 2014; 542, 25-57.
39. White E, Mehnert J M, Chan C S. Autophagy, Metabolism, and Cancer. Clin Cancer Res. 2015; 21, 5037-5046.
40. Muller P A, Vousden K H. p53 mutations in cancer. Nat Cell Biol. 2013; 15, 2-8.
41. Vousden K H, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137, 413-431.
42. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015; 356, 197-203.
43. Zhang C, Liu J, Wu R, Liang Y, Lin M, Liu J, Chan C S, Hu W, Feng Z. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget. 2014; 5, 5535-5546. doi: 10.18632/ oncotarget.2137.
44. Kondoh H, Lleonart M E, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65, 177-185.
45. Contractor T, Harris C R. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012; 72, 560-567.
46. Bensaad K, Tsuruta A, Selak M A, Vidal M N, Nakano K, Bartrons R, Gottlieb E, Vousden K H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006; 126, 107-120.
47. Pai E F, Schulz G E. The catalytic mechanism of glutathione reductase as derived from x-ray diffraction analyses of reaction intermediates. J Biol Chem. 1983; 258, 1752-1757.
48. Feng Z, Levine A J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010; 20, 427-434.
49. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008; 10, 611-618.
50. Freed-Pastor W A, Mizuno H, Zhao X, Langerod A, Moon S H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell M J, Osborne T F, Tian B et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148, 244-258.
51. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine A J, Hu W, Feng Z. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013; 4, 2935.
52. Bartesaghi S, Graziano V, Galavotti S, Henriquez N V, Betts J, Saxena J, A D, Karlsson A, Martins L M, Capasso M, Nicotera P, Brandner S, De Laurenzi V et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proc Natl Acad Sci U S A. 2015; 112, 1059-1064.
53. Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014; 2, 10.
54. Gimenez-Roqueplo A P, Favier J, Rustin P, Mourad J J, Plouin P F, Corvol P, Rotig A, Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001; 69, 1186-1197.
55. Pollard P J, Briere J J, Alam N A, Barwell J, Barclay E, Wortham N C, Hunt T, Mitchell M, Olpin S, Moat S J, Hargreaves I P, Heales S J, Chung Y L et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005; 14, 2231-2239.
56. Rofstad E K, Galappathi K, Mathiesen B, Ruud E B. Fluctuating and diffusion-limited hypoxia in hypoxiainduced metastasis. Clin Cancer Res. 2007; 13, 1971-1978.
57. Wang G L, Jiang B H, Rue E A, Semenza G L. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92, 5510-5514.
58. Selak M A, Armour S M, MacKenzie E D, Boulahbel H, Watson D G, Mansfield K D, Pan Y, Simon M C, Thompson C B, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005; 7, 77-85.
59. Bruick R K, McKnight S L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294, 1337-1340.
60. Hirsila M, Koivunen P, Gunzler V, Kivirikko K I, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003; 278, 30772-30780.
61. Isaacs J S, Jung Y J, Mole D R, Lee S, Torres-Cabala C, Chung Y L, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe P J, Linehan W M, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8, 143-153.
62. Zheng L, Mackenzie E D, Karim S A, Hedley A, Blyth K, Kalna G, Watson D G, Szlosarek P, Frezza C, Gottlieb E. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 2013; 1, 12.
63. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp G W, Wolhuter K, Stevens M, Fischer R, Carmeliet P et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/ Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011; 20, 524-537.
64. Ooi A, Wong J C, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min B W, Tan M H, Zhang Z, Yang X J, Zhou M, Gardie B, Molinie V et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011; 20, 511-523.
65. Sullivan L B, Martinez-Garcia E, Nguyen H, Mullen A R, Dufour E, Sudarshan S, Licht J D, Deberardinis RJ, Chandel N S. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell. 2013; 51, 236-248.
66. Ternette N, Yang M, Laroyia M, Kitagawa M, O'Flaherty L, Wolhulter K, Igarashi K, Saito K, Kato K, Fischer R, Berquand A, Kessler B M, Lappin T et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013; 3, 689-700.
67. Brandon M, Baldi P, Wallace D C. Mitochondrial mutations in cancer. Oncogene. 2006; 25, 4647-4662.
68. Lu J, Sharma L K, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009; 19, 802-815.
69. Campanella M, Casswell E, Chong S, Farah Z, Wieckowski M R, Abramov A Y, Tinker A, Duchen M R. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. Cell Metab. 2008; 8, 13-25.
70. Faccenda D, Tan C H, Seraphim A, Duchen M R, Campanella M. IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death Differ. 2013; 20, 686-697.
71. Santacatterina F, Sanchez-Cenizo L, Formentini L, Mobasher M A, Casas E, Rueda C B, Martinez-Reyes I, Nunez de Arenas C, Garcia-Bermudez J, Zapata J M, Sanchez-Arago M, Satrustegui J, Valverde A M et al. Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state. Oncotarget. 2016; 7, 490-508 doi: 10.18632/oncotarget.6357.
72. Faccenda D, Campanella M. Molecular Regulation of the Mitochondrial F(1)F(o)-ATPsynthase: Physiological and Pathological Significance of the Inhibitory Factor 1 (IF(1)). Int J Cell Biol. 2012; 2012, 367934.
73. Yin T, Lu L, Xiong Z, Wei S, Cui D. ATPase inhibitory factor 1 is a prognostic marker and contributes to proliferation and invasion of human gastric cancer cells. Biomed Pharmacother. 2015; 70, 90-96.
74. Wu J, Shan Q, Li P, Wu Y, Xie J, Wang X. ATPase inhibitory factor 1 is a potential prognostic marker for the migration and invasion of glioma. Oncol Lett. 2015; 10, 2075-2080.
75. Frezza C, Zheng L, Tennant DA, Papkovsky D B, Hedley B A, Kalna G, Watson D G, Gottlieb E. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One. 2011; 6, e24411.
76. Merlo A, de Quiros S B, Secades P, Zambrano I, Balbin M, Astudillo A, Scola B, Aristegui M, Suarez C, Chiara M D. Identification of a signaling axis HIF-1alpha/ microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab. 2012; 97, E2194-200.
77. Puissegur M P, Mazure N M, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci J E et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011; 18, 465-478.
78. Figueroa M E, Abdel-Wahab O, Lu C, Ward P S, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez H F, Tallman M S, Sun Z, Wolniak K et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18, 553-567.
79. Cai L, Sutter B M, Li B, Tu B P. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell. 2011; 42, 426-437.
80. McBrian M A, Behbahan I S, Ferrari R, Su T, Huang T W, Li K, Hong C S, Christofk H R, Vogelauer M, Seligson D B, Kurdistani S K. Histone acetylation regulates intracellular pH. Mol Cell. 2013; 49, 310-321.
81. Lu H, Li G, Liu L, Feng L, Wang X, Jin H. Regulation and function of mitophagy in development and cancer. Autophagy. 2013; 9, 1720-1736.
82. Chourasia A H, Boland M L, Macleod K F. Mitophagy and cancer. Cancer Metab. 2015; 3, 4.
83. Dvorak H F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315, 1650-1659.
84. Swann J B, Smyth M J. Immune surveillance of tumors. J Clin Invest. 2007; 117, 1137-1146.
85. Teng M W, Swann J B, Koebel C M, Schreiber R D, Smyth M J. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008; 84, 988-993.
86. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007; 121, 1-14.
87. Vajdic C M, van Leeuwen M T. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009; 125, 1747-1754.
88. Coffelt S B, Lewis C E, Naldini L, Brown J M, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol. 2010; 176, 1564-1576.
89. DeNardo D G, Andreu P, Coussens L M. Interactions between lymphocytes and myeloid cells regulate proversus anti-tumor immunity. Cancer Metastasis Rev. 2010; 29, 309-316.
90. Johansson M, Denardo D G, Coussens L M. Polarized immune responses differentially regulate cancer development. Immunol Rev. 2008; 222, 145-154.
91. Murdoch C, Muthana M, Coffelt S B, Lewis C E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8, 618-631.
92. De Palma M, Murdoch C, Venneri M A, Naldini L, Lewis C E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007; 28, 519-524.
93. Biswas S K, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11, 889-896.
94. Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J. 1990; 9, 1503-1510.
95. Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J. 2011; 30, 4701-4711.
96. Tannahill G M, Curtis A M, Adamik J, Palsson-McDermott E M, McGettrick A F, Goel G, Frezza C, Bernard N J, Kelly B, Foley N H, Zheng L, Gardet A, Tong Z et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013; 496, 238-242.
97. Dahia P L, Ross K N, Wright M E, Hayashida C Y, Santagata S, Barontini M, Kung A L, Sanso G, Powers J F, Tischler A S, Hodin R, Heitritter S, Moore F et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005; 1, 72-80.
98. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, Schwarzler C, Junt T, Voshol H, Meingassner J G, Mao X, Werner G, Rot A et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol. 2008; 9, 1261-1269.
99. Wyckoff J, Wang W, Lin E Y, Wang Y, Pixley F, Stanley E R, Graf T, Pollard J W, Segall J, Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004; 64, 7022-7029.
100. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008; 454, 436-444.
101. Martinez F O, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008; 13, 453-461.
102. Oshimori N, Oristian D, Fuchs E. TGF-beta Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma. Cell. 2015; 160, 963-976.
103. Jiang L, Xiao L, Sugiura H, Huang X, Ali A, Kuro-O M, Deberardinis RJ, Boothman DA. Metabolic reprogramming during TGFbeta1-induced epithelial-tomesenchymal transition. Oncogene. 2014; 0
104. Porporato P E, Payen V L, Perez-Escuredo J, De Saedeleer C J, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, Feron O, Michiels C, Gallez B et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014; 8, 754-766.
105. Ferreira-da-Silva A, Valacca C, Rios E, Populo H, Soares P, Sobrinho-Simoes M, Scorrano L, Maximo V, Campello S. Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. PLoS One. 2015; 10, e0122308.
106. Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff D W, Abel P W, Tu Y. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013; 32, 4814-4824.
107. Wan Y Y, Zhang J F, Yang Z J, Jiang L P, Wei Y F, Lai Q N, Wang J B, Xin H B, Han X J. Involvement of Drp1 in hypoxia-induced migration of human glioblastoma U251 cells. Oncol Rep. 2014; 32, 619-626.
108. Campello S, Lacalle R A, Bettella M, Manes S, Scorrano L, Viola A. Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. J Exp Med. 2006; 203, 2879-2886.
109. da Silva A F, Mariotti F R, Maximo V, Campello S. Mitochondria dynamism: of shape, transport and cell migration. Cell Mol Life Sci. 2014; 71, 2313-2324.
110. Corrado M, Scorrano L, Campello S. Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. Int J Cell Biol. 2012; 2012, 729290.
111. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem. 2007; 282, 11521-11529.
112. Hackenbrock C R. Ultrastructural bases for metabolically linked mechanical activity in mitochondria. I. Reversible ultrastructural changes with change in metabolic steady state in isolated liver mitochondria. J Cell Biol. 1966; 30, 269-297.
113. Suen D F, Norris K L, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev. 2008; 22, 1577-1590.
114. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko G V, Rudka T, Bartoli D, Polishuck R S, Danial N N, De Strooper B, Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006; 126, 177-189.
115. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, Craessaerts K, Metzger K, Frezza C, Annaert W, D'Adamio L, Derks C, Dejaegere T, Pellegrini L et al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell. 2006; 126, 163-175.
116. Cogliati S, Frezza C, Soriano M E, Varanita T, Quintana-Cabrera R, Corrado M, Cipolat S, Costa V, Casarin A, Gomes L C, Perales-Clemente E, Salviati L, Fernandez-Silva P et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell. 2013; 155, 160-171.
117. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005; 5, 641-654.
118. Altuntas S, Rossin F, Marsella C, D'Eletto M, Diaz-Hidalgo L, Farrace M G, Campanella M, Antonioli M, Fimia G M, Piacentini M. The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation. Oncotarget. 2015; 6, 44941-44954. doi: 10.18632/ oncotarget.6759.
119. Rossin F, D'Eletto M, Falasca L, Sepe S, Cocco S, Fimia G M, Campanella M, Mastroberardino P G, Farrace M G, Piacentini M. Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis. Cell Death Differ. 2015; 22, 408-418.
120. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109, 3812-3819.
121. Dietl K, Renner K, Dettmer K, Timischl B, Eberhart K, Dorn C, Hellerbrand C, Kastenberger M, Kunz-Schughart L A, Oefner P J, Andreesen R, Gottfried E, Kreutz M P. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol. 2010; 184, 1200-1209.
122. Aspuria P J, Lunt S Y, Varemo L, Vergnes L, Gozo M, Beach J A, Salumbides B, Reue K, Wiedemeyer W R, Nielsen J, Karlan B Y, Orsulic S. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2014; 2, 21.
123. Baumann F, Leukel P, Doerfelt A, Beier C P, Dettmer K, Oefner P J, Kastenberger M, Kreutz M, Nickl-Jockschat T, Bogdahn U, Bosserhoff A K, Hau P. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol. 2009; 11, 368-380.
124. Joyce J A, Pollard J W. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9, 239-252.
125. Yizhak K, Le Devedec S E, Rogkoti V M, Baenke F, de Boer V C, Frezza C, Schulze A, van de Water B, Ruppin E. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol Syst Biol. 2014; 10, 744.
126. Mockler M B, Conroy M J, Lysaght J. Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol. 2014; 4, 107.
127. Chang C H, Qiu J, O'Sullivan D, Buck M D, Noguchi T, Curtis J D, Chen Q, Gindin M, Gubin M M, van der Windt G J, Tonc E, Schreiber R D, Pearce E J et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162, 1229-1241.
128. Ho P C, Bihuniak J D, Macintyre A N, Staron M, Liu X, Amezquita R, Tsui Y C, Cui G, Micevic G, Perales J C, Kleinstein S H, Abel E D, Insogna K L et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Antitumor T Cell Responses. Cell. 2015; 162, 1217-1228.
129. van der Windt G J, O'Sullivan D, Everts B, Huang S C, Buck M D, Curtis J D, Chang C H, Smith A M, Ai T, Faubert B, Jones R G, Pearce E J, Pearce E L. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A. 2013; 110, 14336-14341.
130. van der Windt G J, Everts B, Chang C H, Curtis J D, Freitas T C, Amiel E, Pearce E J, Pearce E L. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012; 36, 68-78.
131. Verbist K C, Wang R, Green D R. T cell metabolism and the immune response. Semin Immunol. 2012; 24, 399-404.
132. Gubser P M, Bantug G R, Razik L, Fischer M, Dimeloe S, Hoenger G, Durovic B, Jauch A, Hess C. Rapid effector function of memory CD8+ T cells requires an immediateearly glycolytic switch. Nat Immunol. 2013; 14, 1064-1072.
133. Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, Bland E J, Bombardieri M, Pitzalis C, Perretti M, Marelli-Berg F M, Mauro C. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLoS Biol. 2015; 13, e1002202.
134. Michalek R D, Gerriets V A, Jacobs S R, Macintyre A N, MacIver N J, Mason E F, Sullivan S A, Nichols A G, Rathmell J C. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011; 186, 3299-3303.
135. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 2015; 36, 81-91.
136. De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C, Romano A, De Simone S, Procaccini C, La Rocca C, Carrieri P B, Maniscalco G T, Salvetti M et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015; 16, 1174-1184.
137. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008; 3, e2599.
138. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala A Q, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini J L, Zitvogel L, Kroemer G. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014; 21, 79-91.
139. Schenk U, Westendorf A M, Radaelli E, Casati A, Ferro M, Fumagalli M, Verderio C, Buer J, Scanziani E, Grassi F. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal. 2008; 1, ra6.
140. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel P A, Junger W G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009; 23, 1685-1693.
141. Wang C M, Ploia C, Anselmi F, Sarukhan A, Viola A. Adenosine triphosphate acts as a paracrine signaling molecule to reduce the motility of T cells. EMBO J. 2014; 33, 1354-1364.
142. Goere D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. Cancer Res. 2013; 73, 4663-4673.
143. Ma Y, Adjemian S, Yang H, Catani J P, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala A Q, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology. 2013; 2, e24568.
144. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua M L, Rossini P M, Battistini L, Rotzschke O et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110, 1225-1232.
145. Deaglio S, Dwyer K M, Gao W, Friedman D, Usheva A, Erat A, Chen J F, Enjyoji K, Linden J, Oukka M, Kuchroo V K, Strom T B, Robson S C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204, 1257-1265.
146. Parodi A, Battaglia F, Kalli F, Ferrera F, Conteduca G, Tardito S, Stringara S, Ivaldi F, Negrini S, Borgonovo G, Simonato A, Traverso P, Carmignani G et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol Immunother. 2013; 62, 851-862.
147. Regateiro F S, Howie D, Nolan K F, Agorogiannis E I, Greaves D R, Cobbold S P, Waldmann H. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol. 2011; 41, 2955-2965.
148. Chang C H, Curtis J D, Maggi L B J, Faubert B, Villarino A V, O'Sullivan D, Huang S C, van der Windt G J, Blagih J, Qiu J, Weber J D, Pearce E J, Jones R G et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013; 153, 1239-1251.
149. Gubin M M, Zhang X, Schuster H, Caron E, Ward J P, Noguchi T, Ivanova Y, Hundal J, Arthur C D, Krebber W J, Mulder G E, Toebes M, Vesely M D et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515, 577-581.
150. Kreamer K M. Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. J Adv Pract Oncol. 2014; 5, 418-431.
151. Baitsch L, Legat A, Barba L, Fuertes Marraco S A, Rivals J P, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigenspecificity and anatomical localization. PLoS One. 2012; 7, e30852.
152. Parry R V, Chemnitz J M, Frauwirth K A, Lanfranco A R, Braunstein I, Kobayashi S V, Linsley P S, Thompson C B, Riley J L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005; 25, 9543-9553.
153. Mockler M B, Conroy M J, Lysaght J. Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol. 2014; 4, 107.
154. Rodriguez P C, Quiceno D G, Zabaleta J, Ortiz B, Zea A H, Piazuelo M B, Delgado A, Correa P, Brayer J, Sotomayor E M, Antonia S, Ochoa J B, Ochoa A C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004; 64, 5839-5849.
155. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde B J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003; 9, 1269-1274.
156. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006; 95, 1555-1561.
157. Srivastava M K, Sinha P, Clements V K, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010; 70, 68-77.
158. Wang S F, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquere K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps N B, Cazes A, Gibault L et al. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One. 2011; 6, e17621.
159. Munn D H, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2015; 39, 1-6.
160. Sukumar M, Liu J, Mehta G U, Patel S J, Roychoudhuri R, Crompton J G, Klebanoff C A, Ji Y, Li P, Yu Z, Whitehill G D, Clever D, Eil R L et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 2015.